Organon - OGN EV/Sales Multiple

Organon & Co (OGN) - corporate logo

Biosimilars and women's health therapies provide stable income for Organon & Co. (OGN), with the market having already priced in patent risks. Licensing agreements with biotech startups support portfolio growth. A global warehouse network minimizes supply chain disruptions, confirming the EV/Sales value on the GURU.Markets chart, where 1762.92 reflects the latest business valuation metric relative to revenue, excluding debt.

OGN: Organon Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Organon Corp (OGN)

- stock value and consensus price forecast:
Basic company analysis:Organon (OGN)
Finished products of Organon & Co

Generic pressure on Organon & Co. (OGN) revenue and a high debt load make classic market capitalization misleading. By analyzing the company's EV/Sales ratio, an investor sees the real relationship between enterprise value and turnover, stripped of debt, which helps identify artificial price stabilization and the risk of an asset collapse given the abnormal smoothness of the curve against the backdrop of an industry crisis.